Johnson & Johnson header image

Johnson & Johnson

JNJ

Equity

ISIN null / Valor 943981

New York Stock Exchange, Inc (2026-02-26)
USD 243.47-0.69%

Johnson & Johnson
UMushroom community rating:

star star star star star
4.23 33 votes No rating yet
NegativeNeutralPositive

About company

Johnson & Johnson is a diversified global healthcare company headquartered in New Brunswick, N.J., that, after spinning off its consumer‑health brands into Kenvue in 2023, is primarily organized around pharmaceuticals (Janssen) and medical devices. Its pharmaceutical business develops and commercializes prescription drugs and biologics across areas such as immunology, oncology, infectious disease and neuroscience, while its medtech operations supply a broad range of hospital and clinic products — including orthopedics, surgery, interventional solutions and vision care — sold through commercial and institutional channels worldwide. The company combines internal R&D with partnerships and acquisitions to advance its pipeline, operates global manufacturing and distribution networks, and is subject to the regulatory, reimbursement and litigation risks typical for large health‑care manufacturers.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

49.3%1Y
56.1%3Y
53.6%5Y

Performance

19.1%1Y
17.2%3Y
16.7%5Y

Volatility

Market cap

586738 M

Market cap (USD)

Daily traded volume (Shares)

7,172,607

Daily traded volume (Shares)

1 day high/low

144.88 / 142.96

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.23

33 votes
Performance:
starstarstarstarstar
3.90
Innovation:
starstarstarstarstar
3.78
Society:
starstarstarstarstar
3.84
Nature:
starstarstarstarstar
3.65
Pietro Padovani
United Kingdom, 21 Feb 2026
star star star star star
.
Saahas Nair
United Kingdom, 21 Feb 2026
star star star star star
nice
Aleenah Moghal
United Kingdom, 20 Feb 2026
star star star star star
Incredible returns over past year, bullish forecasted outlook

EQUITIES OF THE SAME SECTOR

Vita 34 AG
Vita 34 AG Vita 34 AG Valor: 2333201
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%EUR 5.20
Maternus-Kliniken AG
Maternus-Kliniken AG Maternus-Kliniken AG Valor: 335800
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.06%EUR 0.95
QuidelOrtho Corporation
QuidelOrtho Corporation QuidelOrtho Corporation Valor: 119356965
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.70%USD 22.70
iRhythm Technologies Inc
iRhythm Technologies Inc iRhythm Technologies Inc Valor: 34117792
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.15%USD 140.18
Novartis Inc
Novartis Inc Novartis Inc Valor: 1200526
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.31%CHF 128.10
Savaria Corp
Savaria Corp Savaria Corp Valor: 1385257
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.47%CAD 25.72
Novo Nordisk A/S
Novo Nordisk A/S Novo Nordisk A/S Valor: 461641
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.42%USD 37.62
Merck & Co Inc
Merck & Co Inc Merck & Co Inc Valor: 10683053
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.58%USD 119.30
Pfizer Inc
Pfizer Inc Pfizer Inc Valor: 962004
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.04%USD 27.10
Abbott Laboratories
Abbott Laboratories Abbott Laboratories Valor: 903037
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.31%USD 116.26